JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(2):E10-E15 | DOI: 10.36290/csf.2025.022

The management of vulvovaginal candidiasis: the results of survey in Lviv, Ukraine

Oksana Horodnycha1, Tetiana Ryvak1*, Oksana Nepyivoda2
1 Department of HealthCare Management, Pharmacotherapy and Clinical Pharmacy, Faculty of Pharmacy, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
2 Emergency Hospital of Lviv, Ukraine

Vulvovaginal candidiasis (VVC) is a serious clinical and social issue. The questionnaire-based study was performed to assess the management of VVC in Lviv, Ukraine. Totally 408 women were enrolled in the survey. The lifetime prevalence of VVC was high (72.6 %). 35.8 % of women had VVC during the last year with the predominance of 1 episode (72.6 %). The most common symptoms were vaginal itching and cottage cheese-like vaginal discharge, affecting 89.7 % and 71.7 % of women with VVC, respectively. Stress (57.2 %) was the main self-reported factor associated with the VVC, followed by antibiotic therapy (49.7 %). Only 51.0 % of women with VVC sought a doctor’s help, 35.2 % of women reported about self-treatment. The management of VVC included usage of medicines and nonmedicinal interventions. Oral antifungals and vaginal medicines prevailed (86.2 % and 80.7 % of woman with VVC used them, respectively). The management of VVC was associated with inappropriate interventions, such as the treatment of an asymptomatic sexual partner (22.8 %), vaginal douching (11.0 %), taking oral antifungals with only local effectiveness for gastrointestinal fungal infections (natamycin and nystatin, 15.2 % vs 14.8 % respectively), using of vaginal drugs with none antifungal activity (5.1 %), and incorrect duration of the treatment (29.1 %). Rural residence (p = 0.000) and the absence of higher education (p = 0.001) significantly contribute to the inappropriate management of VVC. The management of VVC is often associated with self-treatment and different inappropriate interventions. Educational programs are required to improve the management of VVC. Pharmacists may significantly contribute to raising patients’ awareness and improving the management of VVC, especially in rural areas.

Keywords: vulvovaginal candidiasis; management; questionnaire-based study; self-treatment; inappropriate interventions

Accepted: June 6, 2025; Published: June 18, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horodnycha O, Ryvak T, Nepyivoda O. The management of vulvovaginal candidiasis: the results of survey in Lviv, Ukraine. Čes. slov. farm. 2025;74(2):E10-15. doi: 10.36290/csf.2025.022.

Zobrazit celý článek

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 18.6.2026

    References

    1. Satora M, Grunwald A, Zaremba B, et al. Treatment of vulvovaginal candidiasis - an overview of guidelines and the latest treatment methods. J Clin Med. 2023;12(16):5376. [Internet]. MDPI; 2023 [cited 2025 May 30]. Available from: https://doi.org/10.3390/jcm12165376 Go to original source... Go to PubMed...
    2. Neal CM, Martens MG. Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis. SAGE Open Med. 2022;10:20503121221115201. [Internet]. SAGE Publications; 2022 [cited 2025 May 30]. Available from: https://doi.org/10.1177/20503121221115201 Go to original source... Go to PubMed...
    3. Willems HME, Ahmed SS, Liu J, et al. Vulvovaginal candidiasis: a current understanding and burning questions. J Fungi (Basel). 2020;6(1):27. [Internet]. MDPI; 2020 [cited 2025 May 30]. Available from: https://doi.org/10.3390/jof6010027 Go to original source... Go to PubMed...
    4. Benedict K, Singleton AL, Jackson BR, et al. Survey of incidence, lifetime prevalence, and treatment of self-reported vulvovaginal candidiasis, United States, 2020. BMC Womens Health. 2022;22(1):147. [Internet]. BioMed Central; 2022 [cited 2025 May 30]. Available from: https://doi.org/10.1186/s12905-022-01741-x Go to original source... Go to PubMed...
    5. Martínez-García E, Martínez-Martínez JC, Martín-Salvador A, et al. Epidemiological profile of patients with vulvovaginal candidiasis from a sexually transmitted infection clinic in Southern Spain. Pathogens. 2023;12(6):756. [Internet]. MDPI; 2023 [cited 2025 May 30]. Available from: https://doi.org/10.3390/pathogens12060756 Go to original source... Go to PubMed...
    6. Donders G, Sziller IO, Paavonen J, et al. Management of recurrent vulvovaginal candidosis: narrative review of the literature and European expert panel opinion. Front Cell Infect Microbiol. 2022;12:934353. [Internet]. Frontiers; 2022 [cited 2025 May 30]. Available from: https://doi.org/10.3389/fcimb.2022.934353 Go to original source... Go to PubMed...
    7. Denning DW, Kneale M, Sobel JD, et al. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339-e347. [Internet]. Elsevier; 2018 [cited 2025 May 30]. Available from: https://doi.org/10.1016/S1473-3099(18)30103-8 Go to original source... Go to PubMed...
    8. Salmanov AG, Netskar IP, Kostikov VV, et al. Vulvovaginal candidiasis after gynecological surgeries and adverse pregnancy outcome in Ukraine: a multicentre study. Wiad Lek. 2023;76(12):2556-2563. [Internet]. Medical Science; 2023 [cited 2025 May 30]. Available from: https://doi.org/10.36740/WLek202312102 Go to original source... Go to PubMed...
    9. Starishko OM, Voronkova YS, Ostanina TH, et al. Vaginal candidiasis among women of reproductive age in Dnipro city (Ukraine): species spectrum of Candida and their susceptibility to antimycotics. Regul Mech Biosyst. 2019;10(2):172-176. [Internet]. Dnipro National University; 2019 [cited 2025 May 30]. Available from: https://doi.org/10.15421/021925 Go to original source...
    10. Romanenko T, Sulimenko O. Vulvovaginal candidiasis therapy in reproductive age women. Reprod Endocrinol. 2020;54:86-88. [Internet]. Ukrainian Association of Reproductive Medicine; 2020 [cited 2025 May 30]. Available from: https://doi.org/10.18370/2309-4117.2020.54.86-88 Go to original source...
    11. Saxon GDGC, Edwards A, Rautemaa-Richardson R, et al. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019). Int J STD AIDS. 2020;31(12):1124-1144. [Internet]. SAGE Publications; 2020 [cited 2025 May 30]. Available from: https://doi.org/10.1177/0956462420943034 Go to original source... Go to PubMed...
    12. Farr A, Effendy I, Tirri BF, et al. Vulvovaginal candidosis (excluding mucocutaneous candidosis): guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020). Geburtshilfe Frauenheilkd. 2021;81(4):398-421. [Internet]. Thieme; 2021 [cited 2025 May 30]. Available from: https://doi.org/10.1055/a-1345-8793 Go to original source... Go to PubMed...
    13. Sherrard J, Wilson J, Donders G, et al. 2018 European (IUSTI/WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-1272. [Internet]. SAGE Publications; 2018 [cited 2025 May 30]. Available from: https://doi.org/10.1177/0956462418785451 Go to original source... Go to PubMed...
    14. Bitew A, Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018;18:94. [Internet]. BioMed Central; 2018 [cited 2025 May 30]. Available from: https://doi.org/10.1186/s12905-018-0607-z Go to original source... Go to PubMed...
    15. Rabi Salih S, Haddad RA, Abid Hassan S. Prevalence of vulvovaginal candidiasis and its association with contraceptives. Arch Venez Farmacol Ter. 2021;4(4):1-5. [Internet]. Venezuelan Society of Pharmacology; 2021 [cited 2025 May 30]. Available from: https://doi.org/10.5281/zenodo.5224567 Go to original source...
    16. Blostein F, Levin-Sparenberg E, Wagner J, et al. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27(9):575-582.e3. [Internet]. Elsevier; 2017 [cited 2025 May 30]. Available from: https://doi.org/10.1016/j.annepidem.2017.08.010 Go to original source... Go to PubMed...
    17. Huang SH, Hsu HC, Lee TF, et al. Prevalence, associated factors, and appropriateness of empirical treatment of trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis among women with vaginitis. Microbiol Spectr. 2023;11(3):e0016123. [Internet]. American Society for Microbiology; 2023 [cited 2025 May 30]. Available from: https://doi.org/10.1128/spectrum.00161-23 Go to original source... Go to PubMed...
    18. Sustr V, Foessleitner P, Kiss H, et al. Vulvovaginal candidosis: current concepts, challenges and perspectives. J Fungi (Basel). 2020;6(4):267. [Internet]. MDPI; 2020 [cited 2025 May 30]. Available from: https://doi.org/10.3390/jof6040267 Go to original source... Go to PubMed...
    19. Tokak S, Kiliç İ, Horasanli J, et al. Vaginal candidiasis in Konya area: etiology, risk factors, virulence patterns, and antifungal susceptibility. Rev Rom Med Lab. 2021;29(2):201-215. [Internet]. De Gruyter; 2021 [cited 2025 May 30]. Available from: https://doi.org/10.2478/rrlm-2021-0012 Go to original source...
    20. Yang W, Nie Y, Wang S, et al. Previous antibiotic treatment as a risk factor for recurrent vulvovaginal candidiasis. Clin J Obstet Gynaecol. 2019;2:127-132. [Internet]. Scientific Literature; 2019 [cited 2025 May 30]. Available from: https://doi.org/10.29328/journal.cjog.1001034 Go to original source...
    21. Arfiputri DS, Hidayati AN, Handayani S, et al. Risk factors of vulvovaginal candidiasis in dermato-venereology outpatients clinic of Soetomo general hospital, Surabaya, Indonesia. Afr J Infect Dis. 2018;12(1Suppl):90-94. [Internet]. African Journal of Infectious Diseases; 2018 [cited 2025 May 30]. Available from: https://doi.org/10.2101/Ajid.12v1s.13 Go to original source...
    22. Nyirjesy P, Brookhart C, Lazenby G, et al. Vulvovaginal candidiasis: a review of the evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis. 2022;74(Suppl 2):S162-S168. [Internet]. Oxford University Press; 2022 [cited 2025 May 30]. Available from: https://doi.org/10. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.